Sponsors (3)
The bill strengthens commercialization pathways for SBIR/STTR awardees—speeding decisions, adding funding, training, IP support, and reporting—while creating new administrative costs, risks of fund concentration, reporting/privacy burdens, and potential deprioritization of basic/high‑risk research.
Small-business SBIR/STTR applicants will receive faster funding decisions (review deadlines shortened to 180 days), reducing uncertainty and accelerating time-to-market for startups.
Peer review will emphasize commercialization and include reviewers with commercialization expertise, improving selection of projects with market potential and increasing chances of successful commercialization.
More federal agencies will be able to participate (FY2025–2027) and NIH recipients may receive a larger allocation (up to 30%), expanding funding opportunities—particularly for biomedical commercialization.
Emphasis on commercialization and review criteria risks deprioritizing basic, exploratory, or high‑risk research, shifting funding toward near‑term marketable projects and reducing long‑term scientific advances.
Authority to divert up to 10% of agency SBIR/STTR funds (and NIH up to 30%, with a DOD exemption) could reduce funding available for traditional awardees and concentrate resources in certain agencies or areas.
New commercialization mandates, reporting, training options, and USPTO coordination impose additional administrative burdens and staffing costs on agencies and SBA, likely increasing taxpayer expense and diverting staff time from program delivery.
Based on analysis of 8 sections of legislative text.
Refocuses SBIR/STTR on commercialization by shortening decision timelines, adding commercialization peer review, creating Technology Commercialization Officials, funding TBA/I‑Corps participation, and providing patent and reporting support.
Introduced May 7, 2025 by Christina Houlahan · Last progress May 7, 2025
Makes changes to how the federal SBIR and STTR programs prioritize and support commercialization. It shortens some agency decision deadlines, requires commercialization-focused peer review, lets more agencies use a special award authority (with caps), creates designated Technology Commercialization Officials at each participating agency, authorizes set amounts for technical and business assistance and I-Corps participation, mandates an annual commercialization impact assessment, and directs the SBA to partner with the USPTO on prioritized patent help for awardees.